Navigation Links
Lab receives $3 million for BioAMS instrument
Date:10/6/2011

LIVERMORE, Calif. -- Researchers at Lawrence Livermore National Laboratory recently received $3 million from the National Institutes of Health to acquire a new biomedical accelerator mass spectrometry (bioAMS) instrument.

The instrument will provide faster analysis for medical and other biological research.

Historically, no matter what form a biological sample started out in, it had to be converted to graphite before being analyzed in an accelerator. The traditional AMS technology required operation by experts in disciplines far removed from medical fields, unforgiving special chemistries to prepare samples for analysis and extensive time required for that sample preparation -- all factors that have impacted its utility for clinical researchers.

However, in recent years, Lab investments have allowed researchers to develop an interface that would handle liquid samples and bypass the graphitization process. The new bioAMS instrument will couple with this transformational technological development to rapidly and cheaply perform biomedical human subject tracer studies and body burden assessment addressing important questions in nutrition, toxicology, pharmacology, drug development and comparative medicine.

The instrument also will support LLNL's biological detection and medical countermeasures programs. Examples of applications include dating of cancer stem cells, developing individualized patient therapies and rapid testing of new therapeutics against infectious agents.

"AMS fills a special niche in the biomedical field because it can measure very low concentrations of drugs with extreme accuracy, and that's important for helping to understand how biology works. However, its real utility hasn't been fully utilized because of a variety of difficulties," said Ken Turteltaub, principal investigator (PI) of the NIH award and leader of the Lab's bioAMS efforts. "This new technology really moves AMS to the next level."

"In addition," said Ted Ognibene, co-PI of the NIH award, "the new instrument will shrink the standard sample size from half a milligram down to sub microgram levels. This drastically reduced sample size will allow researchers to better match the biological requirements of the experiment with the analytical capabilities of the instrument and open new fields of scientific inquiry that were previously closed with the graphitization approach."

These technological advances were driven by the specific needs of the biomedical community, according to Graham Bench, director of the Center for Accelerator Mass Spectrometry (CAMS). LLNL's National Resource for Biomedical Accelerator Mass Spectrometry works with more than 60 entities around the world on various studies.

"We've held workshops in the past two years for some of our major collaborators, and the number one technological request has been a more user-friendly front end to the instrumentation. They get valuable data out of the AMS, but the sample preparation process is a rather cumbersome step," Bench said. "We've listened to their requests in developing this instrument, because the end game is that they will be able to harness the technology much more effectively."

The new instrument will be the first AMS system at LLNL not housed in CAMS. Rather, it will be deliberately sited in the Lab's bioAMS experimental suite as part of the effort to move the technology out of expert accelerator laboratories into more routine biomedical laboratory settings. LLNL researchers will work to develop and validate the instrument with the goal of deploying the technology to general clinical laboratories in approximately five years.

LLNL's expertise in developing these types of technologies is why the instrument is sited at the Lab, Bench said.

"Livermore invented the field of biomedical AMS, we hold the patents, we are the world leaders," he said. "People come to us for advice and regard what we do as the gold standard for bioAMS. We've always had a reputation of being technologically innovative and they are relying on us to deliver on that yet again."

LLNL's culture of interdisciplinary work is key in maintaining that reputation for technological innovation, Turteltaub added. For example, the bioAMS instrument required researchers with backgrounds in physics, chemistry, biology and biomedical sciences to work closely together. "I don't think this would have happened in an academic or other environment because we truly do things in an interdisciplinary fashion," he said. "This required people with different backgrounds working side-by-side every day. Not collaborating once a week or month, but literally sharing space. This is an institution where the culture is to work right at the edge of what we know, beyond state-of-the-art."

This is only one example of the partnerships needed to create and advance this technology. On a larger scale, support from the National Institutes of Health, National Center for Research Resources, the pharmaceutical industry and academic community were leveraged with Laboratory funding and support from LLNL's Global Security Principal Directorate, Physical and Life Sciences Directorate and Science and Technology office to make this instrument a reality.


'/>"/>
Contact: Breanna Bishop
bishop33@llnl.gov
925-423-9802
DOE/Lawrence Livermore National Laboratory
Source:Eurekalert

Related biology news :

1. Wistar Institute researcher receives New Innovator award from NIH
2. L-1 Identity Solutions Receives $5.9 Million Drivers License Contract Expansion from the State of Mississippi
3. Kount Receives Patent for Device Fingerprinting
4. American College of Medical Genetics receives $13.5M NIH contract
5. Penn State receives new NASA astrobiology grant
6. Global Viral Forecasting Initiative receives $11M to implement pandemic early warning system
7. Vidaza receives positve opinion from European CHMP
8. Case Western Reserve receives Ellison Medical Foundation New Scholar in Aging award
9. Montana State partnership receives $66.9M for carbon sequestration
10. Oklahoma EPSCoR receives $20 million for biofuels research
11. UC Riverside rice geneticist receives high honor from US Department of Agriculture
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/15/2016)... , June 15, 2016 ... market report titled "Gesture Recognition Market by Application Market - Global ... 2016 - 2024". According to the report, the  global ... billion in 2015 and is estimated to grow ... 48.56 billion by 2024.  Increasing application ...
(Date:6/2/2016)... The Department of Transport Management (DOTM) ... million US Dollar project, for the , Supply ... Enrolment, and IT Infrastructure , to ... implementation of Identity Management Solutions. Numerous renowned international vendors participated ... was selected for the most compliant and innovative ...
(Date:5/20/2016)... , May 20, 2016  VoiceIt is ... partnership with VoicePass. By working together, ... experience.  Because VoiceIt and VoicePass take slightly different ... engines increases both security and usability. ... excitement about this new partnership. "This ...
Breaking Biology News(10 mins):
(Date:6/27/2016)...  Liquid Biotech USA , ... Sponsored Research Agreement with The University of Pennsylvania ... cancer patients.  The funding will be used to ... clinical outcomes in cancer patients undergoing a variety ... employed to support the design of a therapeutic, ...
(Date:6/24/2016)... ... ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical journal ... Their findings are the subject of a new article on the Surviving Mesothelioma website. ... the blood, lung fluid or tissue of mesothelioma patients that can help point doctors ...
(Date:6/23/2016)... June 23, 2016 A person commits a crime, ... scene to track the criminal down. An outbreak ... and Drug Administration (FDA) uses DNA evidence to track down ... Sound far-fetched? It,s not. The FDA has increasingly used ... investigations of foodborne illnesses. Put as simply as possible, whole ...
(Date:6/23/2016)... 23, 2016   EpiBiome , a precision microbiome ... in debt financing from Silicon Valley Bank (SVB). The ... to advance its drug development efforts, as well as ... "SVB has been an incredible strategic partner to ... traditional bank would provide," said Dr. Aeron Tynes ...
Breaking Biology Technology: